Market Overview

According to fortune business insights, the global genomics market was valued at USD 34.23 billion in 2025. The market is projected to grow from USD 38.24 billion in 2026 to USD 99.26 billion by 2034, exhibiting a CAGR of 12.66% during the forecast period. North America dominated the genomics market with a market share of 43.04% in 2025.

The analysis shows that the healthcare environment has gradually shifted from conventional treatment methods to precision medicine. The need for storage, sequencing, and analysis of large DNA information for the diagnosis and treatment of critical diseases such as cancer has significantly contributed to driving the market in recent years. This trend indicates strong growth for genomics worldwide.

Major Players Profiled in the Market Report:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Agilent Technologies, Inc. (U.S.)
• Oxford Nanopore Technologies (U.K.)
• Danaher (U.S.)
• QIAGEN (Germany)
• BGI (China)
• IntegraGen (France)
• General Electric Company (U.S.)

Segments

Launch of New Software and Automated Sequencers to Foster Products Segment Growth
Based on type, the market is segmented into products and services. The products segment holds the largest market share due to high volume demand and usage of consumables, coupled with the introduction of new software and fully automated products to analyze large amounts of genetic information.

Widespread Use of PCR to Drive Technology Segment Growth
By technology, the market is categorized into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others. The PCR segment is leading the market, accounting for 47.25% of the market share in 2026, owing to its widespread use and availability.

High Demand in Clinical Applications to Drive Diagnostics Segment Expansion
Based on application, the market is segmented into diagnostics, research, and others. The diagnostics segment holds the largest market share, with 50.42% in 2026, owing to the emergence of direct-to-consumer genetic testing and the increasing use of NGS technology for clinical diagnostics.

Increased Government Research Funding to Drive Research Institutes Segment
Based on end user, the market is split into research institutes, healthcare facilities & diagnostic centers, pharmaceutical & biotechnological companies, and contract research organizations. The research institutes segment leads market growth, accounting for 39.32% of the market share in 2026, owing to increased research funding and strong support from governments.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941

Report Coverage

The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
• Comprehensive insights into regional developments.
• List of major industry players.
• Key strategies adopted by the market players.
• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & Restraints

Rising Number of Government-aided Genome Projects to Propel Market Growth
The rapid growth in government-funded genome projects is a key factor driving market growth. Genomic research is an important tool for developing effective therapies, leading government agencies worldwide to invest in large-scale projects like India's Genome India Project (GIP) and the U.K.'s Genomic Medicine Service. These initiatives generate massive amounts of data, accelerating research and the development of precision healthcare.

However, a shortage of trained technicians with the skill set required to use sophisticated sequencers, particularly in developing countries, may hamper market growth. Additionally, the high cost of instruments and challenges associated with the secure storage of large amounts of data are other restraining factors.

Regional Insights

Rapid Adoption of New Sequencing Technologies Propels Market Growth in North America
North America holds the dominant genomics market share and is projected to experience growth during the forecast period. The region’s growth is attributed to the rapid adoption of new sequencing technologies, a shift towards personalized medicines, and significant government support, such as the Biden Administration's USD 1.7 billion investment to fight COVID-19 variants through expanded genomic sequencing.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to increased demand for genetic sequencing and testing in China, advances in bioinformatics, and rapidly expanding biotechnology sectors in China and India.

Genomics Market Future Growth:

The genomics market is experiencing robust growth, fueled by technological advancements, rising government investment, and the increasing adoption of personalized medicine. Today's healthcare is increasingly focused on using genomic data for disease prevention, diagnosis, and treatment. The rise of cost-effective NGS, innovative CRISPR gene-editing technologies, and the integration of AI and machine learning are revolutionizing data analysis and interpretation. Additionally, there is a growing market for direct-to-consumer (DTC) services. While North America continues to dominate, the Asia-Pacific region is seeing a surge in demand, driven by government initiatives and growing R&D investment.

Competitive Landscape

Strategic Acquisitions and Collaborations to Fortify Market Position
The market features prominent players like Illumina, Inc. and Thermo Fisher Scientific Inc. These leading companies are accelerating growth through strategic initiatives such as a diverse product portfolio, a strong geographic presence, and mergers and acquisitions. For example, Illumina's acquisition of GRAIL aims to advance the early detection of cancer, strengthening its market leadership. Their proactive approach to innovation and strategic partnerships continues to fuel the market’s momentum.

Key Industry Development

• January 2024: Gencove and Ferris Genomics announced a collaboration for end-to-end genomics sequencing services.
• November 2023: MedGenome and PacBio announced a grant for the De Novo Genome Assembly and Annotation.
• December 2022: The U.K. government announced an investment of USD 190 million for genomic research.

What’s Driving Japan’s Market? Discover the Latest Genomics Market Insights